Biora Therapeutics, Inc. Total Liabilities
Biora Therapeutics, Inc. total liabilities. Based on the latest financial reports, Biora Therapeutics, Inc. (BIORQ) has total liabilities worth $121.13 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BIORQ financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biora Therapeutics, Inc. (2018–2023)
Total liabilities of Biora Therapeutics, Inc. from 2018 to 2023. This chart illustrates how Biora Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore BIORQ long-term investments to assets to see how much of total assets are deployed in long-term investments.
Biora Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Biora Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Orion Equities Ltd
AU:OEQ
|
Australia | AU$254.12K |
|
Ridgestone Mining Inc
V:RMI
|
Canada | CA$779.37K |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
Indonesia | Rp569.64 Billion |
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
Germany | €35.06 Million |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
USA | $121.13 Million |
|
IG Design Group plc
LSE:IGR
|
UK | GBX100.86 Million |
|
Foresight Ventures VCT plc
LSE:FVEN
|
UK | GBX2.04 Million |
|
Wingara AG Ltd
AU:WNR
|
Australia | AU$1.31 Million |
Liability Composition Analysis (2018–2023)
This chart breaks down Biora Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Biora Therapeutics, Inc..
Liquidity & Leverage Metrics
Biora Therapeutics, Inc. Total Liabilities Ratios Explained
Biora Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 8.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biora Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biora Therapeutics, Inc. (2018–2023)
The table below shows the annual total liabilities of Biora Therapeutics, Inc. from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $132.64 Million | -14.87% |
| 2022-12-31 | $155.81 Million | -19.61% |
| 2021-12-31 | $193.81 Million | -25.86% |
| 2020-12-31 | $261.43 Million | +40.86% |
| 2019-12-31 | $185.60 Million | +21.02% |
| 2018-12-31 | $153.37 Million | -- |
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more